

1

2 Isolation of *Mycobacterium avium* subsp.  
3 *paratuberculosis* from milk of commercial  
4 consumption in Argentina

5

6

7

8

9

10

11 F. Paolicchi<sup>1,2</sup>, K. Cirone<sup>1,2</sup>, C. Morsella<sup>1</sup>, A. Gioffre<sup>3</sup>, A. Cataldi<sup>3</sup>,  
12 M. Romano<sup>3</sup>

13

14

15

16

17

18

19

20

21

22<sup>1</sup> Laboratory of Bacteriology, Animal Health Group, INTA, Argentina

23<sup>2</sup> Faculty of Agrarian Sciences, National University of Mar del Plata,

24 Argentina

25<sup>3</sup> Institut of Biotechnology, INTA Castelar, Argentina

26 **ABSTRACT:** The objective of this study was to investigate if viable  
27 *Mycobacterium avium* subsp *paratuberculosis* (*Map*) is present in commercial

1pasteurized milk in Argentina. Seventy commercial milk (18 pasteurized, 30  
2ultra-pasteurized and 22 ultra-pasteurized high temperature were collected over  
3seven months. Milk samples (50 ml) were centrifuged and the pellet was  
4suspended in 0.75% of hexadecylpyridinium over night. and the pellet  
5inoculated on Herrold's egg yolk medium with mycobactin and sodium pyruvate.  
6*Map* was isolated from 2 (2.86 %) of 70 pasteurized milk, one from pasteurized  
7and other from ultra-pasteurized milk. Both positive culture samples were also  
8positive with *IS900*-PCR. The isolates were analyzed by PCR and the RFLP of  
9these isolates were pattern A, one of the most prevalent *Map* type in Argentina.  
10This study provides evidence that viable *Map* is present in commercially  
11pasteurized milk. This result has become very important since human exposure  
12to *Map* is a potential risk for Crohn's disease.

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29**Keywords:** Johnes disease, *Mycobacterium avium* subsp *paratuberculosis*,  
30milk, *IS900*

31

32**INTRODUCTION**

1        *Mycobacterium avium* subsp. *paratuberculosis* (*Map*) is the causative  
2agent of paratuberculosis (PTBC) or Johne's disease. It affects domestic and  
3wild animals and causes chronic enteritis in cows, producing symptoms such as  
4diarrhea, weight loss, and progressive emaciation that can eventually lead to  
5death (Collins *et al.*, 1996). *Map* has been also linked to human Crohn's  
6disease, a systemic disorder that causes mainly a chronic inflammation of the  
7intestine. During the development of this pathology, *Map* can parasitize  
8immunoregulatory cells in the intestine of people with acquired or inherited  
9susceptibility, thus resulting in an immunodepression of the mucosal lining of  
10the intestine. This causes symptoms such as profuse diarrhea, inflammation of  
11lymphatic ganglions and intestine, general immunological depression and  
12weakening (Hermon-Taylor, 2002).

13        In the last ten years, there has been important progress in the research  
14of the relationship between this microorganism and Crohn's disease. This  
15research has mainly focused on food products as the transmission pathway.  
16The dogma that *Map* is not a zoonotic microorganism is changing due to recent  
17reports of two cases. The first case is that of a 36-year-old patient with  
18haemophilia, AIDS and low amount of lymphocytes in blood who developed a  
19profuse diarrhea; acid alcohol-resistant bacilli were visualized in the biopsy of  
20his colon, liver and bone marrow, and both the culture analyses and PCR were  
21positive (Richter *et al.*, 2002). The second case was that of a six-year-old boy  
22from whom *Map* was isolated by means of a culture obtained from his lymph  
23nodes (Greenstein, 2003).

24        Although the etiologic agent of the PTBC grows slowly in culture media,  
25this method continues to be the best for its detection. There are other fast,  
26sensitive and specific methods for the detection of the disease such as the  
27polymerase chain reaction (PCR) and the search for restriction fragment length  
28polymorphism (RFLP). These analyses are based on the identification of IS900,  
29an insertion sequence that appears to belong only to *Map* (Green *et al.*, 1989).  
30The way in which *Map* is transmitted is not fully understood yet, but some lines  
31of evidence suggest that humans can get infected through contaminated milk,  
32although relatively little is known about the survival of *Map* during the  
33production of milk. Some authors suggest that pasteurization is capable of

1destroying mycobacteria. Stabel *et al.* (2001) have shown that when milk is  
2inoculated with *Map* and subjected to a treatment of 65°C for 30 minutes, such  
3mycobacteria are destroyed since no viable microorganisms were found after  
428 days of incubation. Likewise, Pearce *et al.* (2002) have stated that the  
5pasteurization under commercial conditions provides an effective inactivation of  
6*Map*, regardless of the type of milk or the recovery medium. In contrast, other  
7authors support the theory that when *Map* is present in milk, it is able to resist  
8the pasteurization conditions (Grant 1998, Grant *et al.*, 1996, Grant *et al.*, 1997,  
9Grant *et al.*, 1999, Grant *et al.*, 2000, Grant *et al.*, 2002a, Grant *et al.*, 2002b,  
10Grant *et al.*, 2003; Grant 2006, Millar *et al.*, 1996).

11 In United Kingdom, viable *Map* has been detected in 1.7 % of samples of  
12commercial pasteurized milk (Grant *et al.*, 2002a) and in 6.7 % of samples of  
13naturally infected raw milk subjected to commercial scale pasteurization at 72°C  
14for 15 or 25 s (Grant *et al.*, 2002b). In addition, viable organisms have been  
15found in a low number of bottles of commercial pasteurized milk in California,  
16Minnesota and Wisconsin (USA). Two point eight percent of the 702 samples  
17analyzed contained viable *Map* (Ellingson, 2005). These results indicate that  
18this pathogen is occasionally capable of surviving commercial pasteurization.  
19Recently, in Czech Republic were tested powdered infant milk from seven  
20countries and IS900 were detected in 49% of samples and using real time PCR  
21were detected the fragment f57 in 35% of them. Additionally, one sample were  
22positive by culture showed viable *Map* is present (Hruska *et al.*, 2005).

23 Goat's milk, which is frequently consumed without pasteurization, can  
24contain cells of *Map* and could constitute a potential source for human  
25infection. This mycobacterium could also be present in cheese and other  
26products that are produced with non-pasteurized milk (Cirone, 2004).

27The objective of the present work was to identify the presence of *Map* in  
28commercial pasteurized milk to different thermal treatments.

29

30

31

32

### 33**MATERIALS AND METHODS**

#### 34**Samples collected**

1 One-liter bottles of fluid milk commercial scale in supermarkets were  
2 purchased at random over seven months (once a month). Eighteen  
3 pasteurized milk (*past*) and thirty ultra pasteurized (*upast*) were kept at 4-6°C,  
4 and twenty-two bottles of ultra high temperature (*uat*), were kept at room  
5 temperature.

6

#### 7 **Treatment of milk samples**

8 Fifty ml of milk was taken from each of 70 samples, transferred to sterile  
9 plastic tubes and centrifuged at 2500 *g* for 30 min; the supernatant was  
10 withdrawn to obtain the pellet. The *upast* and *uat* milk were not subjected to  
11 decontamination processes with hexadecylpyridinium (HPC) at 0.75%. The  
12 *past* milk was decontaminated over night (ON) since it may contain  
13 contaminant microorganisms.

14

#### 15 **Laboratory examination for mycobacteria**

16 **Culture examination.** The pellet from the non-decontaminated samples was  
17 re-suspended in 25 ml of saline buffer pH 7 (PBS), while that from the  
18 decontaminated ones was re-suspended in 25ml of HPC at 0.75%. The  
19 samples were agitated until complete dissolution, and kept at room  
20 temperature ON. They were centrifuged at 2000 *g* for 30 minutes, 1 ml broth  
21 brain-heart (with vancomycin, amphotericyn and nalidixic acid) was added to  
22 each pellet, and they were kept at 37°C ON. Six drops (120 µl) were taken from  
23 each sample, and cultured in triplicate in Herrold's medium (H), H medium plus  
24 mycobactin and piruvate (HMP), and H medium plus mycobactin and  
25 antibiotics (HMA) (Paolicchi, 2003). The cultures were observed every 15 days  
26 for four months, and the development of suspicious colonies of Map was  
27 identified. The colonies were analyzed microscopically by means of Ziehl  
28 Neelsen staining. The counts were expressed in cfu/ml of milk.

29 **Identification of mycobacterial isolates.** Two cfu of the growth of each  
30 of the strains was taken from an HMP culture medium kept at 37°C with colony  
31 development and an aliquot of the reaction mixture was added. The extracted  
32 DNA was amplified in a reaction mixture containing: 2.5 µl of each primer  
33 IS900 (50 ng/µl), P90 5' (GAAGGGTGTTCGGGGCCGTC) and P91

1(GAGGTCGATCGCCCACGTGAC) (Khare *et al.*, 2004), 5 µl of the buffer 10 x  
2(200mM Tris HCl pH 8.4, 500 mM KCl and 50 mM MgCl<sub>2</sub>), 4µl dNTP mix (2.5  
3mM of each dNTP), and 0.25 µl of *Taq* polymerase (5 units/µl) per reaction.  
4Each sample was homogenized and transferred to a tube of PCR in aliquots of  
520 µl. Each mixture was covered with mineral oil and submitted to  
6amplification. The samples were subjected to 25 cycles at 94°C for 3 minutes,  
7to 94°C for 1 minute, to 65°C for 1 minute and to 72°C for 2 minutes; and to  
8one cycle at 72°C for 4 minutes. For each set of PCRs both a positive (*Map*  
9DNA) and a negative control (sterile distilled water) were used. An aliquot of  
10each mixture of amplification was subjected to electrophoresis in agarose gel  
11at 2% with Tris-borate buffer EDTA (TBE; 89 mM Tris, 1 mM boric acid, 2 mM  
12EDTA). The DNA bands were observed under UV light after ethidium bromide  
13staining. The samples were classified as positive only if the correct band size  
14(217 bp) was identified in the gel.

15 **Analyzed strains.** The two strains isolated from commercial milk were  
16analyzed by using the method described by Paolicchi *et al* (2002). After  
17digestion, the restriction endonuclease *Bst*EII was used and the type of RLFP-  
18IS900 of *Map* isolated was designed arbitrarily by using the letters “A”, “B”, “C”  
19and “E” to design the diferente patterns of RFLP (Moreira *et al.*, 1999; Pavlík  
20*et al.*, 1995; Pavlík *et al.*, 1999).

21

## 22RESULTS

23 Colonies with the typical morphology of *Map* were identified in one *past*  
24and in one *uat* sample of milk after 8 weeks on Herrold’s media (Table 1). Both  
25strains isolated from commercial milk were positive for the PCR IS900.(photo  
261) The results of the RFLP analysis revealed that both strains of *Map* belong to  
27a pattern called “A” or C17 European strains type (photo 2).

28

## 29DISCUSSION

30 *Map* is a microorganism that can be found in different productive  
31systems and in the agricultural-food chain, and thus represents a risk for Public  
32Health. In the present work, we demonstrate that it is possible to identify viable  
33*Map* from the commercial pasteurized milk that was obtained from dairy herds

1 and animals presumably infected with PTBC. This indicates *Map*'s capacity to  
2 resist inactivation by heat treatments to which milk is subjected before  
3 commercialization and consumption. Although the number of milk bottles  
4 examined in this work was low, the positive samples found represent 2.86% of  
5 all samples tested. This finding is the first of its kind in Argentina as regards  
6 commercial milk and indicates the risk of infection to which the population that  
7 usually consumes this product is exposed.

8 The genetic identification in the *Map* strains isolated from commercial  
9 milk revealed that they belong to pattern "A", which is the most important one in  
10 our country. On the other hand, the two strains analyzed by PCR from a colony  
11 of *Map* culture (PCR colony) were positive, thus confirming the identity of this  
12 mycobacterium found in commercial milk.

13 Studies performed in United Kingdom revealed that *Map* is present in  
14 1.7% of samples of commercial pasteurized milk (Grant *et al.*, 2002a). In  
15 addition, viable organisms have been found in low numbers (2.8% of a total of  
16 702 samples) in commercial pasteurized milk in California, Minnesota and  
17 Wisconsin in the USA (Ellingson, 2005). These results indicate that is  
18 pathogen is capable of surviving commercial pasteurization. Due to these  
19 results, certain European governments introduce measures to reduce *Map* in  
20 the food chain as way of preventing of the disease (Greenstein, 2003).

21 An important clinical finding that reinforces the concept of zoonosis is  
22 that *Map* has also been cultured from maternal milk from two women with  
23 Crohn's disease. This was confirmed by means of the detection of the insertion  
24 sequence IS900 typical of *Map* (Naser *et al.*, 2000). Our previous works in  
25 cheese made with cows' and sheep's milk artificially inoculated with *Map*,  
26 indicated that this pathogen would resist the condition of maturation in cheese  
27 (Cirone, 2004).

28 The results obtained in this work, which are important as regards Public  
29 Health, demonstrate that the controls in the sanitary systems in the dairy farm  
30 and milk industry should be tightened with the aim of protecting consumers  
31 from risk of infection with *Map* and any other potentially pathogenic bacteria.

32 Further qualitative and quantitative research is still necessary in order to  
33 clarify the role *Map*'s resistance to heat treatments performed in the milk

1industry, as well as to evaluate its survival to the different elaboration  
2processes used for dairy products. Also, fast, reliable and inexpensive  
3detection methods should be developed so that efficient control measures can  
4be later applied both in primary production and in the manufacture or  
5processing of food.

6 Other similar works should be performed in different regions of  
7Argentina in order to evaluate the presence of *Map* in milk and derived dairy  
8products, and to relate them both to the prevalence of PTBC in cattle and other  
9animal species or to the incidence of Crohn's disease in humans. On the other  
10hand, it would be important to develop and adjust the fast and reliable  
11identification methods to detect the presence of *Map* in food products before  
12they are placed in the market for human consumption.

13

#### 14**ACKNOWLEDGEMENT**

15 The authors are grateful to Dr Irene Grant, Department of Food Science  
16(Food Microbiology), Queen's University of Belfast and Iva Teshinska  
17(Veterinary Research Institut, Czech Republic) by critical reading of  
18manuscript.

19

20

21

22

23

24

25

26

27

28

29

30**Corresponding author: Fernando Paolicchi, CC 276, Balcarce (7620)**

31**Argentina. Phone +54 2266 439 121. Fax +54 266 439120**

32**E-mail address: [fpaolicchi@balcarce.inta.gov.ar](mailto:fpaolicchi@balcarce.inta.gov.ar)**

#### 33**REFERENCES**



1Cirone K. (2004): Characterization and viability of *Mycobacterium avium* subsp.  
2 *paratuberculosis* in milk, cheese and water. (Caracterización y viabilidad de  
3*Mycobacterium avium* subsp. *paratuberculosis* en leche, quesos y agua.)  
4Thesis of Graduate at Universidad Nacional de Mar del Plata, Faculty of  
5Agrarian Sciences. Argentina. 65 p.

6

7Collins M.T., Goodger W.J., Nordlund K.V., Pelletier J. (1996): Associations  
8between subclinical paratuberculosis and milk production, milk components,  
9and somatic cell counts in dairy herds. J Am Vet Med Assoc. 208(11):1872-  
101876.

11

12Ellingson J., Anderson J., Koziczowski J., Radcliff., R., Sloan S., Allen S.,  
13Sullivan N. (2005): Detection of Viable *Mycobacterium avium* subsp.  
14*paratuberculosis* in Retail Pasteurized Whole Milk by Two Culture Methods and  
15PCR; J of Food Prot. 68 (5): 966-972;

16

17Grant I.R., Ball H.J., Neill S.D., Rowe M.T. (1996): Inactivation of  
18*Mycobacterium avium* subsp. *paratuberculosis* in cows' milk at pasteurization  
19temperatures. Appl Environ Microbiol. 62 (2): 631-636.

20

21Grant I.R., Ball H.J., Rowe M.T. (1997): A novel staining technique for  
22assessing clumping and viability of *Mycobacterium avium* subsp.  
23*paratuberculosis* cells during pasteurization; Proceedings of the 5<sup>th</sup>  
24International Colloquium on Paratuberculosis. International Association of  
25Paratuberculosis Inc, Rehoboth, MA, USA. p. 456-458.

26

27Grant I.R. (1998): Letter to the editor: Does *Mycobacterium avium* subsp.  
28*paratuberculosis* survive current pasteurization conditions? Appl Environ  
29Microbiol. (7): 2760-2761.

30

31Grant I.R., Ball H.J., Rowe M.T. (1999): Effect of higher pasteurization  
32temperatures, and longer holding times at 72 degrees C, on the inactivation of  
33*Mycobacterium avium* subsp. *paratuberculosis* in milk. Lett Appl Microbiol. 28  
34(6):461-465.

35

36Grant I.R., Pope C.M., O'Riordan L.M., Ball H.J., Rowe M.T. (2000): Improved  
37detection of *Mycobacterium avium* subsp. *paratuberculosis* in milk by  
38immunomagnetic PCR. J. Vet. Microbiol. 77(3-4):369-378.

39

40Grant I.R., Hitchings E.I, Ball H.J., Rowe M.T. (2002a): Impact of commercial  
41HTST pasteurization on *Mycobacterium avium* subsp. *paratuberculosis* in  
42naturally infected cow's milk. Appl Environ Microbiol. 68(2): 602-607.

43

44Grant I.R., Ball H.J., Rowe M.T. (2002b): Incidence of *Mycobacterium avium*  
45subsp. *paratuberculosis* in bulk raw and commercial pasteurized cow's milk

1from approved dairy processing establishments in the United Kingdom; Appl  
2Environ Microbiol; 68: 2428-2435;

3

4Grant I.R., Kirk E., Hitchings E.I., Rowe M.T. (2003): Comparative evaluation of  
5MGIT and BACTEC culture systems for the recovery of *Mycobacterium avium*  
6subsp. *paratuberculosis* from milk. J Appl Microbiol. 95: 169-201.

7

8Grant I.R. (2006): Occurrence of *Mycobacterium avium* subsp *paratuberculosis*  
9in foods and the impact of milk processing on its survival. Proceeding of 8<sup>o</sup>ICP,  
10Copenhagen, Denmark.

11Green G., Tizard M., Thompson J., Winterbourne D., Mc Fadden J., Hermon-  
12Taylor J. (1989): Sequence and characteristic of IS900, and insertion  
13sequence identified in human Crohn's disease isolate of *Mycobacterium avium*  
14subsp. *paratuberculosis*. Nucleic acid Research. 17: 9063-9073.

15

16Greenstein R. (2003): Is Crohn's disease caused by a mycobacterium?  
17Comparisons with leprosy, tuberculosis, and Johne's disease. The Lancet  
18infectious disease. 3: 507-513.

19

20Hermon-Taylor J. (2002): *Mycobacterium avium* subsp. *paratuberculosis* and  
21its relation to Crohn's disease. Proceedings of the 7<sup>th</sup> International Colloquium  
22on Paratuberculosis. Bilbao, Spain. p. 96

23

24Hruska K., Bartos M., Kralik P., Pavlik I. (2005): *Mycobacterium avium* subsp.  
25*paratuberculosis* in powdered infant formula. Veterinarni Medicina (Vet Med  
26Czech) 50:8.

27

28Khare S., Fitch T., Santos R., Romano J., Fitch A., Zhang S., Grant I., Libal M.,  
29Hunter D., Adams G. (2004): Rapid and sensitive detection of *Mycobacterium*  
30*avium* subsp. *paratuberculosis* in bovine milk and feces by combination of  
31immunomagnetic bead separation-conventional PCR and real-time PCR. J.  
32Clinical Microbiol. 42(3): 1075-1081.

33

34

35

36Millar D., Ford J., Withey S., Tizard M., Doran T., Hermon-Taylor J. (1996):  
37IS900 PCR to detect *Mycobacterium avium* subsp. *paratuberculosis* in retail  
38supplies of whole pasteurized cow's milk in England en Wales. Appl Environ  
39Microbiol. 5(11): 3446-2452.

40

41Moreira A., Paolicchi F., Morsella C., Zumarraga M., Cataldi A., Bigi F., Alito A.,  
42Overduin P., Van Soolingen D., Romano M. (1999): Distribution of IS900  
43restriction length polymorphism types among animal *Mycobacterium avium*  
44subsp. *paratuberculosis* isolates from Argentina and Europe. J Vet Microbiol.  
4570: 251-259.

1

2Naser, S., Schwarz D., Shafran I., (2000): Isolation of *Mycobacterium avium*  
3subsp. *paratuberculosis* from breast milk of Crohn's disease patients. Am J  
4Gastroenterol. 95 (4):1094-1095.

5

6Paolicchi F.A., Zumarraga M.J., Gioffre A., Zamorano P., Morsella C., Verna  
7A., Cataldi A., Alito A., Romano M. (2003): Application of different methods for  
8the diagnosis of paratuberculosis in dairy cattle herds in Argentina. J Vet Med.  
950: 20-26.

10

11Pavlik I., Horvathova A., Bartl J., Rychlik I. (1995): Study of epidemiology and  
12pathogenesis of paratuberculosis using RFLP (Restriction Fragment Length  
13Polymorphism); Proceedings of the Fifth International Colloquium of  
14Paratuberculosis; p. 202-211.

15

16Pavlik I., Horvathova A., Dvoska L., Svastova P., du Maine R., Fixa B., Rychlik  
17I. (1999): Homogeneity / Heterogeneity of *Mycobacterium avium* subsp.  
18*paratuberculosis* strains. Correlation between RFLP-Type and source (Animal,  
19Enviromental, Human). Proceedings of sixth International Colloquium of PTBC.  
20321-329.

21

22Pearce L.E., Crawford R.A., Troung H.T., Yates G.F., Lisle G.W. (2002): The  
23recovery of *Mycobacterium avium* subsp. *paratuberculosis* following heat  
24treatment of inoculated milk in a turbulent-flow pasteuriser is not adversely  
25affected by decontamination and antibiotic selection. Proceedings of the 7<sup>th</sup>  
26International Colloquium on Paratuberculosis. Bilbao, Portugal; p. 102.

27

28Richter E., Wessling J., Lugerling N., Domschke W., Gerdes-Rush S. (2002):  
29*Mycobacterium avium* subsp. *paratuberculosis* Infection in a patient with HIV,  
30Germany. Emerging Infectious Disease. 8 (7): 729-730;

31Stabel J.R. (2001): On-farm batch pasteurization destroys *Mycobacterium*  
32*avium* subsp. *paratuberculosis* in waste milk. J Dairy Sci. 84 (2):524-527.

33

34**Table 1:**

35Results of cultivated milk samples .

36

37Type of milk	Milk samples (%) with <i>Map</i>
39 <i>past</i> <sup>a</sup>	1 (5.56%)
40 <i>upast</i> <sup>b</sup>	0 (0 %)
41 <i>uat</i> <sup>c</sup>	1 (4.55 %)
42total number	<b>2 (2.86 %)</b>

43

44a.pasteurized

1b. ultra-pasteurized

2c. ultra- high temperature

3

4

5

6

7

8

9

10

11

12

13

14

15

